Toxicity of chronic ayahuasca administration to the pregnant rat: How relevant it is regarding the human, ritual use of ayahuasca?

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 6, 2010, Pages 533-535

  Dos Santos, Rafael Guimarães ^a  

^a Interdisciplinary Group for Psychoactive Studies   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALKALOID; BETA CARBOLINE; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; HARMALINE; HARMINE; LYSERGIDE; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AYAHUASCA; BRAZIL; FEMALE; INFERIOR OLIVE; LD 50; LETTER; LONG TERM EXPOSURE; MEDICINAL PLANT; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PURKINJE CELL; RAT; REPRODUCTIVE TOXICITY; RITUAL;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; BANISTERIOPSIS; BIOLOGICAL AVAILABILITY; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; HUMANS; MATERNAL EXPOSURE; PREGNANCY; RATS; RATS, WISTAR; RESEARCH DESIGN; RISK ASSESSMENT; SPECIES SPECIFICITY;

BANISTERIOPSIS CAAPI; RATTUS;

EID: 78650218931     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20272     Document Type: Letter

References (27)

1. Callaway JC. 2005a. Fast and slow metabolizers of Hoasca. J Psychoactive Drugs 37:157-161.
2. Callaway JC. 2005b. Various alkaloid profiles in decoctions of Banisteriopsis caapi. J Psychoactive Drugs 37:151-155.
3. Callaway JC, McKenna DJ, Grob CS, et al. 1999. Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol 65:243-256.
4. da Silveira DX, Grob CS, Dobkin de Rios M, et al. 2005. Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs 37:129-133.
5. de la Torre R, Farré M. 2004. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
6. Doering-Silveira E. 2003. Avaliação neuropsicológica de adolescentes que consomem chá de ayahuasca em contexto ritual religioso. Thesis. Unifesp/EPM.
7. Doering-Silveira E, Lopez E, Grob CS, et al. 2005. Ayahuasca in adolescence: a neuropsychological assessment. J Psychoactive Drugs 37:123-128.
8. Fábregas JM. 2010. Long term effects on mental health of ayahuasca ritual use. Psychedelic Science in the 21st Century-An International Conference Offering Continuing Medical Education Credits. April 15-18, San Jose, CA.
9. Fantegrossi WE, Woolverton WL, Kilbourn M, et al. 2004. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29:1270-1281.
10. Grob CS, McKenna DJ, Callaway JC, et al. 1996. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184:86-94.
11. Halky JJ. 1974. The effects of dextroamphetamine, dimethyltryptamine, lysergic acid diethylamide and tetrahydrocannabinol upon pregnancy and the offspring. Thesis. University of Kansas. [abstract].
12. Halpern JH, Sherwood AR, Passie T, et al. 2008. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14:SR15-SR22.
13. Kamel SH, Ibrahim TH, Hamza SM. 1971. Effect of harmine and harmaline hydrochloride on pregnancy in white rats. Zentralbl Veterinärmed A 18:230-233.
14. Lyvers, M. 2006. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues. Drug Alcohol Rev 25:269-276.
15. McIlhenny EH, Pipkin KE, Standish LJ, et al. 2009. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr A, 1216:8960-8968.
16. Miwa H, Kubo T, Suzuki A, et al. 2006. A species-specific difference in the effects of harmaline on the rodent olivocerebellar system. Brain Res 1068:94-101.
17. O'Hearn E, Molliver ME. 1993. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55:303-310.
18. O'Hearn E, Molliver ME. 1997. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci 17:8828-8841.
19. Oliveira CDR, Moreira CQ, de Sá LRM, et al. 2010. Maternal and developmental toxicity of ayahuasca in Wistar rats. Birth Defects Res B Dev Reprod Toxicol 89:207-212.
20. Ott J. 1999. Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs 31:171-177.
21. Passie T, Halpern JH, Stichtenoth DO, et al. 2008. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295-314.
22. Pires APS, De Oliveira CDR, Moura S, et al. 2009. Gas chromatographic analysis of dimethyltryptamine and β-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Phytochem Anal 20:149-153.
23. Poulson E, Robson JM. 1963. The effect of amine oxidase inhibitors on pregnancy. J Endocrinol 27:147-155.
24. Riba J. 2003. Human pharmacology of ayahuasca. Thesis. Universitat Autònoma de Barcelona, Barcelona, Spain.
25. Riba J, Valle M, Urbano G, et al. 2003. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306:73-83.
26. Wu C, Jiang XL, Shen HW, Yu AM. 2009. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 78:617-624.
27. Yu AM, Idle JR, Krausz KW, et al. 2003. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic β-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305:315-322.